Ruxolitinib: a new first-line strategy in autoimmune myelofibrosis treatment
Authors:
- 13 July 2023
- journal article
- letter
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (10) , 1-4
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosisAmerican Journal of Hematology, 2018
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseasesNature Reviews Drug Discovery, 2017
- Autoimmune Myelofibrosis: Clinical Features, Course, and OutcomeActa Haematologica, 2017
- Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literatureHuman Pathology, 2014
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory DiseasesJournal of Medicinal Chemistry, 2014
- Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibresBritish Journal of Haematology, 2007
- Peripheral monocytes and CD4+ cells are potential Sources for increased circulating levels of TGF‐β and substance P in autoimmune myelofibrosisAmerican Journal of Hematology, 2005
- Autoimmune myelofibrosis: report of three cases and review of the literature.Leukemia & Lymphoma, 2004
- Idiopathic Myelofibrosis Associated with Classic Polyarteritis NodosaLeukemia & Lymphoma, 2003
- Primary autoimmune myelofibrosis: Definition of a distinct clinicopathologic syndromeAmerican Journal of Hematology, 2002